Adaptive Biotechnologies Corp (ADPT): Cost of Revenue
$71.36M
Year ended 2025-12-31
$75.25M
Trailing 12 months to 2026-06-30
+7.2%
3-year compound annual growth
+25.9%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $71.36M | -1.0% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $72.08M | -4.6% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $75.55M | +30.5% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $57.91M | +17.5% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $49.30M | +118.8% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $22.53M | +1.1% | 2023-02-14, From 2020-01-01 |
| 2019-12-31 | $22.27M | +13.2% | 2022-02-15, From 2019-01-01 |
| 2018-12-31 | $19.67M | +25.4% | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | $15.68M | n/a | 2020-02-26, From 2017-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $71.36M | -1.0% |
| Vericel Corp (VCEL) | 2025-12-31 | $70.66M | +8.5% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $173.18M | +85.7% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $185.57M | +3.3% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $5.09M | +86.3% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $70.0K | n/a |
| REGENXBIO Inc. (RGNX) | 2024-12-31 | $33.57M | -9.8% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $217.41M | +5.1% |
| Agenus Inc (AGEN) | 2025-12-31 | $1.02M | +110.3% |
Compare ADPT, VCEL, IOVA, TWST side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗